Member Info for Aether

MrCosts

Are you still invested?

What do you think the future is for SNG?

Thanks.

The "From another board" thread was just deleted.

Much more!

If we get on a paid trial, it will be more than 25%.

The volume in the US is tiny. So the price fluctuates more than the UK. Hope you're right though!

We have 1-2 years before there is a rights issue.

1-2 years.

We need a TO or successful clinical trial results. Nothing else will budge the sp after The RNS. The market is (rightly) wary.

If not ... finito.

We need:

1. Good Activ-2 data.
2. Inclusion on a paid for clinical trial.

We will probably find out about Activ-2 data in a month or so.

Fingers crossed, and everything else, that the COVID funding Bill passes through the legistlature. I suspect funding new clinical trials will depend on it.

Also, I suspect MrCosts was being sarcastic!

This product needs to be out of Synairgen's hands and into a larger pharma that can get it across the line.

Thanks for the reply.

Do they intend to use this power or is it just a precautionary measure and included every year?

Thank you.

So, what are resolution 12 and 13 for?

This is a small uni-spin off company with one product. Would anyone else do any better. Not sure.

But this company must NOT be allowed to become an AIM lifestyle company with directors being rewarded for failure. Especially catastrophic failure.

So, what are resolution 12 and 13 for?

Resolution 13 looks like stock options for directors?

Surely resolution 12 can't be shares for directors after the The RNS debacle? The biggest f*** up in the companies history? If so, it should be stopped otherwise this risks becoming another AIM lifestyle company for the insiders.

They need to be held to account for the incompetence not rewarded with shares and stock options.

Is there going to be a rights issue?

Holding this share has become stressful without further news.

Activ-2 data should be good because:

(1) Sprinter suggests it works especially for some some groups
(2) NIH allowed progression to P3
(3) NIH officials are working to rewrite the protocol and find a suitable new trial

Although the data from another drug that was allowed to progress was surprisingy average, I suspect, given facts (1) to (3) above, the data will be *at least* above average in quality and probably better than that!

This data is important because, although the sample size is smaller than Sprinter, blood samples were collected that can be used to match genetics to the health outcomes of the patient the drug was administered to. THAT is very commercially valuable and something Sprinter did not do.

The reason for the delay is probably because the Covid funding Bill in the US is being delayed going through the legislature.

So, if and when the funding Bill passes, the Activ-2 data will probably be released and, hopefully, we will be included in a new paid for Activ trial.

THEN, either:

(1) TO
(2) we wait for the outcome of the trial.

I will never invest in AIM stock again or be suckered in by cult-like hype on a forum or hopefully anywhere else.

The sun is shining and am going out for a walk. Life is for living and enjoying. Peace.

Will Polygon just be hands-off and let SNG continue as they normally do?

We have 24 months before the money runs out. So, the sp will only increase with:

1. JV
2. TO
3. Inclusion on clinical trial.

For these to happen we need:

1. Good Activ-2 data.
2. Inclusion on a paid for clinical trial.

Otherwise, it's bottom drawer time.

What stage is the Covid Bill at in the US?

If that passes, funding will be available.

Two brokers are listing this as a Buy.

The Activ-2 data and inclusion on a paid for clinical trial will increase the sp and increase the likelihood of a JV or TO.

Numis lists the price as 220.

Sell your shares crystallize the losses and write it off against future profits.

GLA enjoy the weekend.

Covid is the market that will get us authorisation before the money runs out.

The fact that it has other uses adds to it's potential for any pharmaceutical company considering buying it.

Next steps:
1. AGM.
2. Release of Activ-2 data.
3. Inclusion on a paid for clinical trial.

Then a JV or TO.

GLA and enjoy the long weekend!

The new video is interesting because they include immuno-compromised patients as potentially benefiting from the treatment.

How long can they hold onto the Activ-2 data!?

Initially, I suspected it was because it would be average but now I'm not so sure. I think it will, like Sprinter, be good data.

If the data is good this will dramatically increase the chances of inclusion on a paid for clinical trial.

If the data is VERY good a TO could follow before the clinical trial is completed because after a successful clinical trial the sp will rise significantly.

So, one step at a time:

1. AGM soon.
2. The COVID Bill passes through the legislature.
3. Activ-2 data is released.
4. Inclusion on a paid for clinical trial.

GLA and enjoy the weekend!